{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:40:03Z","timestamp":1761057603558},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":225,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p><jats:bold>Background<\/jats:bold> Previous studies comparing the corticosteroids fluticasone propionate (FP) and budesonide (BUD) in both perennial and seasonal rhinitis have shown no consistent difference between treatments. However, the therapeutic outcomes may have been influenced by study design.<\/jats:p><jats:p><jats:bold>Objective<\/jats:bold> To compare the effect of FP aqueous nasal spray (ANS; 200\u2003\u00b5g\/day) with BUD reservoir powder device (RPD; 200\u2003\u00b5g\/day) on rhinitis symptoms, productivity loss and device preference in patients with perennial rhinitis.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> After a 2\u2010week run\u2010in period, 440 patients were randomized to receive either FPANS, BUD RPD or matched placebo (ANS or RPD) for 8 weeks, followed by an open\u2010label 4\u2010week follow\u2010up treatment with FPANS. Patients completed diary card visual analogue scores for nasal symptoms, and questionnaires on satisfaction with the treatment and preferred choice of device.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> During weeks 1\u20134, the visual analogue total nasal symptom scores (VATNS) in the FPANS group were significantly lower than scores in the BUD RPD group (mean difference =\u221217.8; 95% CI\u2003=\u2003\u221234.4,\u2003\u22121.3; <jats:italic>P<\/jats:italic>\u2003=\u20030.036). FPANS also significantly reduced the VATNS compared with the ANS placebo at all time\u2010points assessed (<jats:italic>P<\/jats:italic>\u2003\u2264\u20030.005). BUD RPD did not significantly differ from the RPD placebo at weeks 5\u20138 (<jats:italic>P<\/jats:italic>\u2003=\u20030.167), or the ANS placebo at any time\u2010point (<jats:italic>P<\/jats:italic>\u2003\u2264\u20030.151). Over the 8\u2010week treatment period FPANS was significantly more effective than BUD RPD at reducing sneezing (mean difference =\u22124.4; 95% CI\u2003=\u2003\u22128.6,\u2003\u22120.3; <jats:italic>P<\/jats:italic>\u2003=\u20030.036) and nasal itching (mean difference =\u22125.3; 95% CI\u2003=\u2003\u22129.9,\u2003\u22120.8; <jats:italic>P<\/jats:italic>\u2003=\u20030.022), and was significantly superior to the ANS placebo for all symptoms assessed at weeks 1\u20134 and 1\u20138 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.016). At the same time\u2010points BUD RPD was no better at alleviating nasal itching than the RPD placebo (<jats:italic>P<\/jats:italic>\u2003\u2264\u20030.306), and compared with the ANS placebo, significantly reduced only one symptom; nasal blockage (<jats:italic>P<\/jats:italic>\u2003\u2264\u20030.016). After 8 weeks of treatment, patients preferred the ANS device to the RPD (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), and at 12\u2003weeks a significantly greater number of patients were satisfied with FPANS treatment compared with BUD RPD (<jats:italic>P<\/jats:italic>\u2003=\u20030.0019) or the respective placebos (<jats:italic>P<\/jats:italic>\u2003=\u20030.0001).<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> FPANS and BUD RPD are effective therapies with a good safety profile for the treatment of perennial rhinitis but, in this direct placebo\u2010controlled comparison, FPANS was more efficacious than BUD RPD, and the patients preferred the ANS device to the RPD.<\/jats:p>","DOI":"10.1046\/j.1365-2222.2001.01097.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T09:48:00Z","timestamp":1047376080000},"page":"855-863","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of once daily fluticasone propionate aqueous nasal spray with once daily budesonide reservoir powder device in patients with perennial rhinitis"],"prefix":"10.1111","volume":"31","author":[{"given":"E.","family":"Kivisaari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(08)80004-2"},{"key":"e_1_2_6_3_2","first-page":"459","article-title":"Oral bioavailability of fluticasone propionate in healthy subjects","volume":"41","author":"Falcoz C","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_6_4_2","first-page":"158","article-title":"Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations","volume":"45","author":"Daley\u2010Yates P","year":"1988","journal-title":"Eur J Allergy Clin Immunol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199714010-00006"},{"key":"e_1_2_6_6_2","first-page":"435","article-title":"Double\u2010blind comparison of intranasal fluticasone propionate, 200 micrograms, once daily with 200 micrograms twice daily in the treatment of patients with severe seasonal allergic rhinitis to ragweed","volume":"72","author":"Dolovich J","year":"1994","journal-title":"Ann Allergy"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb05051.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.92.4.594"},{"key":"e_1_2_6_9_2","first-page":"169","article-title":"A multicentre study to assess long\u2010term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis","volume":"31","author":"Haye R","year":"1993","journal-title":"Rhinol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.1996.tb00103.x"},{"key":"e_1_2_6_11_2","first-page":"240","article-title":"Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis","volume":"73","author":"Banov CH","year":"1994","journal-title":"Ann Allergy"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753050-00014"},{"key":"e_1_2_6_13_2","first-page":"18","article-title":"A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis","volume":"33","author":"Andersson M","year":"1995","journal-title":"Rhinol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2500\/105065897781446658"},{"key":"e_1_2_6_15_2","first-page":"585","article-title":"Inhaled fluticasone propionate is a potent inhibitor of PAF\u2010induced eosinophil accumulation in guinea\u2010pig lung","volume":"6","author":"Hughes S","year":"1993","journal-title":"Eur Respir J"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447020-00007"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90039-7"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998309109815"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2273.1984.tb01503.x"},{"key":"e_1_2_6_20_2","first-page":"225","article-title":"Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire","volume":"70","author":"Juniper EF","year":"1993","journal-title":"Ann Allergy"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1991.tb00627.x"},{"key":"e_1_2_6_22_2","first-page":"77","article-title":"Deposition pattern from a nasal pump spray","volume":"25","author":"Newman SP","year":"1987","journal-title":"Rhinol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1995.tb05747.x"},{"key":"e_1_2_6_24_2","first-page":"7","article-title":"Nasal distribution of budesonide inhaled via a powder inhaler","volume":"31","author":"Thorsson L","year":"1993","journal-title":"Rhinol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(93)90317-9"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1995.tb00011.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2273.1998.00096.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70354-9"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1986.tb00298.x"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2222.2001.01097.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2222.2001.01097.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2222.2001.01097.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T17:57:21Z","timestamp":1697565441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2222.2001.01097.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1046\/j.1365-2222.2001.01097.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2222.2001.01097.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}